PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07444645

Enrollment

Registered

2026-03-03

Start date

2026-08-01

Completion date

2030-07-31

Last updated

2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver, Tumor

Brief summary

This single-arm prospective study will compare CT-based tumor-to-normal ratio (TNR) measurements obtained using TriNav versus endhole microcatheters.

Detailed description

Primary Objective: Primary Objective #1: To evaluate the alterations in CT-based relative enhancement ratio from non-contrast to post-contrast CT imaging in the tumor and normal liver with an FDA-cleared Pressure Enabled Drug DeliveryTM (PEDDTM) device aka TriNav Infusion System. Secondary Objectives: To evaluate the correlation of CT-based relative enhancement with tumor to normal liver ratio (TNR) from Tc99m-MAA SPECT/CT mapping study, and tumor dose (TD), nontumoral liver dose (NTLD), and tumor microparticle load from the post-Y90 treatment SPECT/CT in patients mapped and treated with TriNav Infusion System. To assess safety of TriNav catheter in this study population

Interventions

DEVICEY90 Microsphere Therapy

Given by injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DEVICE_FEASIBILITY

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent 2. Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months 3. At least one lesion ≥ 3.0 cm in shortest dimension 4. Negative pregnancy test in premenopausal women with an acceptable contraception 5. Plan to perform bilobar, lobar or sectoral treatment using partition dosimetry 6. Evidence of partial or complete tumor vascularity based on pre-procedure liver protocol CT scan or MRI with contrast or intraprocedural hybrid angio CT as well as subjectively similar tumor vascularity between right and left lobes if bilobar treatment is planned 7. Right or left hepatic artery diameter of 1.5 mm to 5 mm (the recommended vessel size range for the TriNav Infusion System) based on pre-procedure arterial phase CT or intraprocedural hybrid angio CT

Exclusion criteria

1. Contraindications to angiography and selective visceral catheterization 2. Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single treatment session 3. CT based TNR of 3 or higher based on planning hybrid angioCT 4. Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels) 5. Infiltrative tumors

Design outcomes

Primary

Measure	Time frame	Description
Safety and Adverse Events (AEs)	Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Countries

United States

Contacts

CONTACTPeiman Habibollahi, MD

phabibollahi@mdanderson.org(713) 792-4106

PRINCIPAL_INVESTIGATORPeiman Habibollahi, MD

M.D. Anderson Cancer Center

PRINCIPAL_INVESTIGATORS. Cheenu Kappadath, PHD